Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.
Increased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM1). These ac...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4583449?pdf=render |
id |
doaj-a62dbb4ce5a34f169230d3bb37502d5d |
---|---|
record_format |
Article |
spelling |
doaj-a62dbb4ce5a34f169230d3bb37502d5d2020-11-25T00:23:38ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01109e013921210.1371/journal.pone.0139212Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.Sandra Gouveia-FigueiraJessica KarlssonAlessandro DeplanoSanaz HashemianMona SvenssonMarcus Fredriksson SundbomCenzo CongiuValentina OnnisChristopher J FowlerIncreased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM1). These activities are shown by Flu-AM1 racemate, but it is not known whether its two single enantiomers behave differently, as is the case towards COX-2 for the parent flurbiprofen enantiomers. Further, the effects of the compound upon COX-2-derived lipids in intact cells are not known.COX inhibition was determined using an oxygraphic method with arachidonic acid and 2-arachidonoylglycerol (2-AG) as substrates. FAAH was assayed in mouse brain homogenates using anandamide (AEA) as substrate. Lipidomic analysis was conducted in unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Both enantiomers inhibited COX-2 in a substrate-selective and time-dependent manner, with IC50 values in the absence of a preincubation phase of: (R)-Flu-AM1, COX-1 (arachidonic acid) 6 μM; COX-2 (arachidonic acid) 20 μM; COX-2 (2-AG) 1 μM; (S)-Flu-AM1, COX-1 (arachidonic acid) 3 μM; COX-2 (arachidonic acid) 10 μM; COX-2 (2-AG) 0.7 μM. The compounds showed no enantiomeric selectivity in their FAAH inhibitory properties. (R)-Flu-AM1 (10 μM) greatly inhibited the production of prostaglandin D2 and E2 in both unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Levels of 2-AG were not affected either by (R)-Flu-AM1 or by 10 μM flurbiprofen, either alone or in combination with the FAAH inhibitor URB597 (1 μM).Both enantiomers of Flu-AM1 are more potent inhibitors of 2-AG compared to arachidonic acid oxygenation by COX-2. Inhibition of COX in lipopolysaccharide + interferon γ- stimulated RAW 264.7 cells is insufficient to affect 2-AG levels despite the large induction of COX-2 produced by this treatment.http://europepmc.org/articles/PMC4583449?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sandra Gouveia-Figueira Jessica Karlsson Alessandro Deplano Sanaz Hashemian Mona Svensson Marcus Fredriksson Sundbom Cenzo Congiu Valentina Onnis Christopher J Fowler |
spellingShingle |
Sandra Gouveia-Figueira Jessica Karlsson Alessandro Deplano Sanaz Hashemian Mona Svensson Marcus Fredriksson Sundbom Cenzo Congiu Valentina Onnis Christopher J Fowler Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor. PLoS ONE |
author_facet |
Sandra Gouveia-Figueira Jessica Karlsson Alessandro Deplano Sanaz Hashemian Mona Svensson Marcus Fredriksson Sundbom Cenzo Congiu Valentina Onnis Christopher J Fowler |
author_sort |
Sandra Gouveia-Figueira |
title |
Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor. |
title_short |
Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor. |
title_full |
Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor. |
title_fullStr |
Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor. |
title_full_unstemmed |
Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor. |
title_sort |
characterisation of (r)-2-(2-fluorobiphenyl-4-yl)-n-(3-methylpyridin-2-yl)propanamide as a dual fatty acid amide hydrolase: cyclooxygenase inhibitor. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
Increased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM1). These activities are shown by Flu-AM1 racemate, but it is not known whether its two single enantiomers behave differently, as is the case towards COX-2 for the parent flurbiprofen enantiomers. Further, the effects of the compound upon COX-2-derived lipids in intact cells are not known.COX inhibition was determined using an oxygraphic method with arachidonic acid and 2-arachidonoylglycerol (2-AG) as substrates. FAAH was assayed in mouse brain homogenates using anandamide (AEA) as substrate. Lipidomic analysis was conducted in unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Both enantiomers inhibited COX-2 in a substrate-selective and time-dependent manner, with IC50 values in the absence of a preincubation phase of: (R)-Flu-AM1, COX-1 (arachidonic acid) 6 μM; COX-2 (arachidonic acid) 20 μM; COX-2 (2-AG) 1 μM; (S)-Flu-AM1, COX-1 (arachidonic acid) 3 μM; COX-2 (arachidonic acid) 10 μM; COX-2 (2-AG) 0.7 μM. The compounds showed no enantiomeric selectivity in their FAAH inhibitory properties. (R)-Flu-AM1 (10 μM) greatly inhibited the production of prostaglandin D2 and E2 in both unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Levels of 2-AG were not affected either by (R)-Flu-AM1 or by 10 μM flurbiprofen, either alone or in combination with the FAAH inhibitor URB597 (1 μM).Both enantiomers of Flu-AM1 are more potent inhibitors of 2-AG compared to arachidonic acid oxygenation by COX-2. Inhibition of COX in lipopolysaccharide + interferon γ- stimulated RAW 264.7 cells is insufficient to affect 2-AG levels despite the large induction of COX-2 produced by this treatment. |
url |
http://europepmc.org/articles/PMC4583449?pdf=render |
work_keys_str_mv |
AT sandragouveiafigueira characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT jessicakarlsson characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT alessandrodeplano characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT sanazhashemian characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT monasvensson characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT marcusfredrikssonsundbom characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT cenzocongiu characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT valentinaonnis characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT christopherjfowler characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor |
_version_ |
1725355744676544512 |